How Immunotherapy Differs from Chemotherapy
When facing a cancer diagnosis, understanding the available treatment options is important. Among the most prominent approaches are immunotherapy vs chemotherapy, two strategies that work against cancer in fundamentally different ways, each with its own benefits and risks.
Key Takeaways
- Core Mechanisms: Chemotherapy directly attacks rapidly dividing cells, while immunotherapy works with the body’s own immune system to help it recognize and destroy cancer cells.
- Targeting: Immunotherapy is often more selective, targeting specific markers on cancer cells or immune checkpoints. Chemotherapy has a broader, systemic effect, reaching both cancerous and healthy rapidly dividing cells.
- Side Effects: Chemotherapy commonly causes systemic side effects such as hair loss and nausea. Immunotherapy can cause immune-related adverse events, which are inflammatory reactions that can affect various organs. Each treatment’s side effect profile is different, and which one a person experiences depends on the specific drug and their individual health.
- Outcomes: Immunotherapy can lead to a durable, long-term response in some patients with certain cancers, though it does not work for everyone. Chemotherapy typically aims for more rapid tumor reduction, and recurrence can be a concern with either approach.
- Patient Experience: The patient experience, including the nature and management of side effects, varies significantly between these two treatment approaches and from person to person.
Immunotherapy vs Chemotherapy: Core Mechanisms
The fundamental differences between immunotherapy and chemotherapy lie in how each works in the body. Both aim to eliminate cancer cells, but their approaches differ substantially, which affects their side effects and how patients experience treatment.
Immunotherapy: Harnessing the Immune System
Rather than directly attacking cancer cells, immunotherapy works by stimulating or restoring the immune system’s ability to recognize and destroy malignant cells. This includes approaches such as checkpoint inhibitors, which release a brake on immune cells, and other strategies where a patient’s own immune cells are involved in targeting cancer. Because the immune system can develop a memory response, this approach can, for some patients, lead to a response that continues after treatment ends — though this is not the case for everyone.
Chemotherapy: Direct Cell Attack
Chemotherapy uses drugs designed to kill rapidly dividing cells throughout the body. Because cancer cells divide rapidly and without normal controls, they are a primary target for these drugs. However, chemotherapy is not selective — it also affects other fast-dividing healthy cells, such as those in hair follicles, bone marrow, and the lining of the digestive tract. This non-specific action is a key reason chemotherapy’s side effects differ from immunotherapy’s. Chemotherapy is generally used with the goal of reducing tumor size relatively quickly.
Targeting Cancer Cells and Treatment Scope
How precisely each treatment targets cancer cells, and how broad its effect is on the body, are both important factors in comparing immunotherapy and chemotherapy. This affects efficacy, side effects, and which treatment may be suitable for a given cancer.
Specificity of Immunotherapy
One characteristic of immunotherapy is its relative specificity. Immunotherapy drugs are designed to interact with particular molecules on cancer cells or immune cells, allowing for a more targeted approach. Checkpoint inhibitors, for example, block proteins that cancer cells use to evade immune detection. Because healthy cells are generally spared from this direct mechanism, immunotherapy tends to have a different side effect profile than chemotherapy — not necessarily a lighter one, since immune-related side effects can still be serious and can affect any organ.
Broad Impact of Chemotherapy
Chemotherapy has a broad, systemic effect. Its drugs circulate through the bloodstream, reaching cancer cells in various parts of the body, which can be useful for widespread or metastatic disease. This broad reach comes at the cost of also affecting healthy, rapidly dividing cells, which is why patients undergoing chemotherapy often experience systemic side effects such as hair loss, nausea, fatigue, and increased susceptibility to infection. Chemotherapy remains a foundational treatment for many cancers, valued in part for its ability to reduce tumor burden relatively quickly, even though its lack of selectivity is a defining feature of its side effect profile.
Side Effects and Patient Experience
Understanding the distinct side effect profiles of chemotherapy and immunotherapy is important for patients and healthcare providers alike. Both treatments can cause adverse reactions, but their underlying mechanisms lead to different patient experiences.
Immunotherapy’s Immune-Related Adverse Events
Because immunotherapy works by activating the immune system, its side effects — known as immune-related adverse events — stem from an overactive immune response. These can show up as inflammation in various organs. Commonly reported immune-related adverse events include:
- Skin reactions: rash, itching.
- Gastrointestinal issues: colitis (inflammation of the colon), diarrhea.
- Endocrine changes: thyroid dysfunction and other hormone-related effects.
- Liver inflammation (hepatitis) and lung inflammation (pneumonitis), which are less common.
These reactions can range from mild to severe and call for careful monitoring, often with corticosteroids to calm the immune response. Severe reactions are less common than chemotherapy’s systemic effects but can be serious and may require specialized care from an oncologist or other specialist.
Chemotherapy’s Systemic Side Effects
Chemotherapy’s non-selective effect on rapidly dividing cells leads to a range of systemic side effects. These are often predictable and well documented, though severity varies among individuals and specific drug regimens. Common systemic side effects include:
- Nausea and vomiting, related to the drugs’ effect on the digestive lining.
- Hair loss (alopecia), affecting hair follicles.
- Fatigue, a common and sometimes significant side effect.
- Lower blood cell counts, which can lead to anemia, a higher risk of infection (neutropenia), or easier bruising and bleeding (thrombocytopenia).
- Mouth sores (mucositis), an inflammation of the mucous membranes.
- Nerve problems (peripheral neuropathy), which can cause numbness or tingling.
Managing these side effects is a significant part of chemotherapy treatment, and supportive care can play an important role in helping patients maintain their quality of life during therapy.
Treatment Outcomes and Benefits
Comparing immunotherapy and chemotherapy also means looking at their potential outcomes and the different benefits each may offer. Both have strengths, and they often play different roles in cancer care — sometimes together.
Potential for Long-Term Remission
One potential benefit associated with immunotherapy, in certain cancers, is the possibility of a durable, long-term response, including in some advanced cancers. Because immunotherapy trains the immune system to recognize cancer cells, some patients develop an immune memory that may continue to help control the disease after active treatment ends. Checkpoint inhibitor drugs have FDA-approved uses in several cancers, melanoma and lung cancer among them, and some patients with these and other advanced cancers go on to experience a lasting response. This does not happen for every patient, and how a person responds depends on their specific cancer and individual health.
Rapid Tumor Reduction
Chemotherapy, by contrast, is often effective at achieving a relatively rapid reduction in tumor size. Its direct effect on dividing cells can shrink tumors, ease symptoms, and provide more immediate relief for patients with large or fast-growing cancers. This rapid response can matter in situations where prompt disease control is needed, such as when a tumor is pressing on a vital organ or causing significant pain. While chemotherapy does not typically produce the same kind of lasting immune memory associated with immunotherapy in some patients, its ability to reduce tumor size relatively quickly makes it a valuable tool, often used together with other therapies or as a primary treatment for cancers that respond well to it.
Ultimately, immunotherapy and chemotherapy differ in their mechanisms, targeting, side effect profiles, and potential benefits. The choice between these therapies — or a combination of both — is a decision made by an oncology team, based on the individual patient’s cancer type, stage, overall health, and treatment goals.
Frequently Asked Questions
What is the main difference between immunotherapy and chemotherapy?
The main difference is in their approach: chemotherapy directly attacks and kills rapidly dividing cells, including cancer cells and some healthy cells, which leads to systemic side effects. Immunotherapy instead works by stimulating or enhancing the body’s own immune system to recognize and destroy cancer cells. This affects how each treatment targets cancer, its side effect profile, and its potential for long-term disease control.
Can immunotherapy and chemotherapy be used together?
Yes, the two are often used in combination. This approach aims to draw on the strengths of both treatments — chemotherapy can reduce tumor burden relatively quickly, while immunotherapy can add a more targeted, potentially durable immune response. Combining therapies can improve outcomes for some cancers, though it may also add complexity to managing side effects.
Which treatment is more effective for cancer, immunotherapy or chemotherapy?
Neither treatment is universally more effective than the other; how well each works depends heavily on the specific type and stage of cancer, as well as individual patient factors. Chemotherapy is often useful for reducing tumor size relatively quickly, while immunotherapy may offer the potential for a longer-term response in certain cancers. The right treatment strategy is always personalized, often involving a combination of therapies, and is chosen with an oncology team to fit the individual patient.
Sources
